April 28th 2025
Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.
Watch the series now!
Bundled Payments and Other Cost-Management Approaches to Oncology Care
Responding to Patient Needs Central to Providing Value in Cancer Care
Cancer Trial Participants Can Successfully Self-Report Adverse Events